✍️ Trichometrics Editorial Team·🩺 Reviewed for medical accuracy
For informational purposes only — consult a healthcare provider before starting treatment.
Pattern Hair Loss

Androgenetic Alopecia: The Complete Guide

Androgenetic alopecia, commonly called male or female pattern baldness, is the most prevalent form of hair loss worldwide. Understanding how DHT drives follicle miniaturization is the foundation of every effective treatment strategy.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment. Individual results may vary.

How Common Is It?

Androgenetic alopecia is not rare, it is the statistical norm for aging men and an extremely common experience for women.

80M

Americans affected by androgenetic alopecia, the most common form of hair loss by far

, AHLA

50%

of men show clinically detectable signs by age 50; 70% by age 70

, Hamilton-Norwood data

~65%

of finasteride users experience significant regrowth or halted progression in clinical trials

, Kaufman et al., 1998

How It Works: DHT and Follicle Miniaturization

The condition is driven by a combination of genetic predisposition and the androgen hormone DHT, not by stress, diet, or hat-wearing.

Genetic Sensitivity

Hair follicles in susceptible scalp regions (temples, crown) contain androgen receptors that are particularly sensitive to DHT. This sensitivity is genetically programmed and present from birth.

DHT-Driven Miniaturization

Dihydrotestosterone (DHT) binds to androgen receptors in sensitive follicles, shortening the anagen (growth) phase with each cycle. Over years, terminal hairs progressively miniaturize into vellus hairs before the follicle ceases production.

Follicle Cycling Changes

A key early marker is increased hair shedding as follicles cycle faster but produce shorter, finer hairs. Over time, the growth phase shortens from years to weeks.

Inflammation Component

Emerging research suggests perifollicular micro-inflammation plays a role, particularly in more aggressive cases. This has prompted interest in anti-inflammatory adjuncts like ketoconazole shampoo alongside standard treatments.

Key insight: The back and sides of the scalp contain follicles that are genetically resistant to DHT. This is why they remain, and why hair transplants work by moving these resistant follicles to thinning areas.

Norwood Scale: Stages of Progression

The Hamilton-Norwood scale classifies male pattern baldness into 7 stages. Knowing your stage guides treatment urgency and options.

Stage I–II

Early. Best time to act

Slight recession at temples; hairline barely changed. Often dismissed as normal variation. This is the ideal window to start preventive treatment.

Stage III

Moderate. Act now

Clearly visible recession at temples and/or early vertex thinning. Most people first seek help at this stage. Good treatment response expected.

Stage IV–V

Advanced. Slow progression

Significant frontal recession and/or a bald spot at the crown, with a remaining bridge of hair between them. Treatment can slow or halt further loss.

Stage VI–VII

Severe. Transplant candidate

The bridge of hair has thinned or disappeared; front and crown merge into extensive baldness. Treatment mainly prevents further loss; transplant often considered.

For women, the Ludwig scale (Grades I–III) describes diffuse thinning at the crown with a preserved frontal hairline, the typical female pattern.

Evidence-Based Treatment Options

Treatments work best when started early. The goal is to block DHT, stimulate follicles, or physically replace lost hair.

Finasteride (1mg oral)

FDA-Approved

A 5-alpha reductase inhibitor that blocks the conversion of testosterone to DHT, reducing scalp DHT by ~70%. The most evidence-backed oral treatment. FDA-approved. Significant regrowth or stabilization in ~85% of men. Requires long-term use.

Minoxidil (Topical or Oral)

FDA-Approved (Topical)

Topical minoxidil (2% or 5%) applied to the scalp prolongs the anagen phase and increases follicle size. Oral minoxidil (0.25–2.5mg) is increasingly used off-label with strong results. Works independently of DHT and can be combined with finasteride.

Dutasteride

Off-Label (Stronger)

Inhibits both type I and type II 5-alpha reductase (vs finasteride's type II only), reducing scalp DHT by ~90%. Not FDA-approved for hair loss in the US but widely used off-label and approved in several countries. Stronger evidence than finasteride in head-to-head trials.

Hair Transplant (FUE/FUT)

Surgical

Surgical redistribution of DHT-resistant follicles from the back and sides to the top of the scalp. The transplanted hairs retain their original genetic resistance. Permanent results, but does not stop progression in native hairs, so medical treatment is still recommended alongside surgery.

Combination therapy is typically more effective than any single agent. Finasteride + minoxidil is the gold-standard combination, with some adding ketoconazole shampoo for its mild anti-androgenic scalp effects.

Diagnosis: How Is It Confirmed?

Androgenetic alopecia is primarily a clinical diagnosis. But ruling out other causes is important before starting treatment.

Clinical Examination

A dermatologist assesses the pattern and distribution of thinning. The characteristic pattern (temples and crown in men; top of scalp with preserved hairline in women) is often diagnostic on its own.

Trichoscopy

A non-invasive scalp imaging technique that reveals hair diameter variability (anisotrichosis), a hallmark of androgenetic alopecia visible under 20–70x magnification. Can detect miniaturization early, before it's visible to the naked eye.

Blood Tests

To rule out thyroid dysfunction, iron deficiency (ferritin), hormonal imbalances, and nutritional deficiencies. Not required to diagnose AGA, but essential to exclude reversible causes, especially in women.

Scalp Biopsy

Rarely needed. Reserved for ambiguous cases. A punch biopsy can confirm the ratio of terminal to vellus hairs and detect inflammatory conditions that may co-exist with or mimic AGA.

Track Your Progress with AI

Androgenetic alopecia progresses slowly, making it easy to underestimate until significant loss has occurred. Trichometrics uses AI to analyze and compare your scalp photos over time, giving you objective data on whether you're stable, progressing, or responding to treatment.

Start Tracking Free

Frequently Asked Questions

Is androgenetic alopecia permanent?

Androgenetic alopecia is a chronic, progressive condition, without treatment, hair loss will continue. However, it is not permanent in the sense that it cannot be slowed or partially reversed. Treatments like minoxidil and finasteride can halt progression and stimulate some regrowth. Hair that has been lost for many years, where follicles have been replaced by scar tissue, is generally not recoverable. Early intervention produces the best outcomes.

At what age does androgenetic alopecia start?

Androgenetic alopecia can begin as early as the late teens or early 20s, though it most commonly becomes noticeable in the 30s and 40s. Roughly 50% of men have clinically detectable androgenetic alopecia by age 50, and 70% by age 70. In women, prevalence rises sharply after menopause due to the decline in protective estrogen.

Is androgenetic alopecia inherited from the mother or father?

Both. Androgenetic alopecia is polygenic, it is inherited from both sides of the family. While the AR gene on the X chromosome (inherited from the mother) plays an important role, research has identified over 200 genetic loci associated with the condition. Looking at your maternal grandfather's hair is not a reliable predictor. Your risk is elevated if either parent or grandparent experienced significant hair loss.

Can androgenetic alopecia be reversed?

Partial reversal is possible with appropriate treatment, particularly in the earlier stages. Minoxidil can stimulate the growth phase and result in visible regrowth in approximately 40-60% of users. Finasteride blocks DHT production and produces regrowth in about 65% of men in clinical trials (Kaufman et al., 1998). Neither medication restores the original density, but significant partial reversal combined with halted progression is achievable for most people who start early.